Regeneron acquired Checkmate Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, for USD 1.1 billion. The acquisition added several new immunotherapy candidates to Regeneron's pipeline, including CMP-001, a bispecific antibody that targets PD-1 and LAG-3, and CMP-002, a T cell engager that targets BCMA.
Regeneron merged its wholly owned subsidiary Regeneron Genetics Center LLC, a US-based genetic testing company, with Myriad Genetics, Inc., a US-based genetic testing company. The merger created a leading genetic testing company with a comprehensive portfolio of tests for a wide range of genetic diseases.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5404
Published Date: Nov 27, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing demand for healthcare sector is the major factor driving the market growth.
The market size of neurotrophins is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.
The major players in the market Genentech, Inc., Regeneron Pharmaceuticals, Inc., Biogen Inc., Amgen Inc., Eli Lilly and Company, Novartis International AG, and others.
The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.